{"analyses":[{"ciLowerLimit":"0.861","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.381","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"P-value comparing OS between treatment groups was based on log-rank test stratified by initial therapy (proteasome inhibitor-containing or not), International Staging System (ISS) stage before initial therapy (stage I or II vs stage III), age (\\<75 versus \\[vs\\] \\>=75 years) at randomization, and best response to initial therapy (complete response (CR) or very good partial response (VGPR) vs partial response (PR)).\n\nHazard ratio was based on an unadjusted Cox's proportional hazard regression model stratified by initial therapy (proteasome inhibitor-containing or not), ISS stage before initial therapy (stage I or II vs stage III), age (\\<75 versus\\[vs\\] \\>=75 years) at randomization, and best response to initial therapy (CR or VGPR vs PR), comparing the hazard rate of ixazomib arm over the hazard rate of placebo arm. A less than 1 hazard ratio was to be considered statistically significant.","pValue":"=0.473","paramType":"Hazard Ratio (HR)","paramValue":"1.090","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.67","upperLimit":"75.17","value":"69.5"},{"groupId":"OG001","lowerLimit":"54.87","upperLimit":"74.84","value":"64.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"281"},{"groupId":"OG001","value":"425"}],"units":"Participants"}],"description":"OS was measured as the time from the date of randomization to the date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.","id":"OG000","title":"Placebo"},{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.","id":"OG001","title":"Ixazomib"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants who were randomized and had post-randomization data.","reportingStatus":"POSTED","timeFrame":"From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}